HDII (Hypertension Diagnostics) EBIT: $0.00 Mil (TTM As of Sep. 2019)


What is Hypertension Diagnostics EBIT?

Hypertension Diagnostics HDII -99.00% EBIT is $0.00 Mil as of Sep. 2019.

Hypertension Diagnostics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2019 was $0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2019 was $0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hypertension Diagnostics's annualized ROC % for the quarter that ended in Sep. 2019 was 0.00%. Hypertension Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Hypertension Diagnostics  (OTCPK:HDII) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hypertension Diagnostics's annualized ROC % for the quarter that ended in Sep. 2019 is calculated as:

ROC % (Q: Sep. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2019 ) + Invested Capital (Q: Sep. 2019 ))/ count )
=0 * ( 1 - 0% )/( (0.572 + 0.572)/ 2 )
=0/0.572
=0.00 %

where

Invested Capital(Q: Jun. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.278 - 1.344 - ( 0.086 - max(0, 1.344 - 0.706+0.086))
=0.572

Invested Capital(Q: Sep. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.278 - 1.344 - ( 0.086 - max(0, 1.344 - 0.706+0.086))
=0.572

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Hypertension Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2019 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2019  Q: Sep. 2019
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (0.51 + max(-0.924, 0)) + (0.51 + max(-0.924, 0)) )/ 2 )
=0/( ( 0.51 + 0.51 )/ 2 )
=0/0.51
=0.00 %

where Working Capital is:

Working Capital(Q: Jun. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.188 + 0.189 + 0.043) - (1.344 + 0 + 0)
=-0.924

Working Capital(Q: Sep. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.188 + 0.189 + 0.043) - (1.344 + 0 + 0)
=-0.924

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hypertension Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2019 )
=0/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypertension Diagnostics EBIT Related Terms

Hypertension Diagnostics EBIT Historical Data

* Premium members only.

The historical data trend for Hypertension Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hypertension Diagnostics EBIT Chart

Hypertension Diagnostics Annual Data
Trend Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Dec16 Dec17 Dec18
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.36 -1.33 -0.47 -0.21 0.04

Hypertension Diagnostics Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Dec16 Dec17 Dec18 Mar19 Jun19 Sep19
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HDII vs ESTRF, OCLN, PTOI: EBIT Comparison

For the Shell Companies subindustry, Hypertension Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hypertension Diagnostics EV-to-EBIT vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Hypertension Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hypertension Diagnostics's EV-to-EBIT falls into.


Hypertension Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $0.00 Mil mean?
Hypertension Diagnostics (HDII) has a EBIT of $0.00 Mil as of Sep. 2019. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hypertension Diagnostics.
Is Hypertension Diagnostics' EBIT too high?
Hypertension Diagnostics' current EBIT is $0.00 Mil.
How does Hypertension Diagnostics' EBIT compare to ESTRF and OCLN?
Hypertension Diagnostics' EBIT of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Diversified Financial Services company?
A good EBIT depends on the Diversified Financial Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hypertension Diagnostics. Hypertension Diagnostics's current EBIT is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypertension Diagnostics stock overvalued right now?
Hypertension Diagnostics (HDII) has a current EBIT of $0.00 Mil. The current EBIT is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hypertension Diagnostics (HDII), the current EBIT is $0.00 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hypertension Diagnostics Business Description

Address 550 Highway 7 Unit 316, Ontario, ON, CAN, L4B324
Hypertension Diagnostics Inc is a shell company.